Company: EUDAW
Filing Date: 2025-10-28
Form Type: 6-K
Source: 0001493152-25-019893
Chunk: 0

Company: EUDA Health Holdings Ltd
Filing Date: 2025-10-28
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-40678

EUDA Health Holdings Limited

(Exact Name of Registrant as Specified in its Charter)

60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: +65 6327 1110</div>

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

New Director

Wong Kong Yew (“Prof. Wong”), an independent director of EUDA Health Holdings Limited (the “Company” or “EUDA”), has resigned from the Board of Directors of the Company and as Chairman of the Compensation Committee, and member of the Audit Committee and Nomination Committee, effective October 23, 2025. Prof. Wong’s resignation was not due to any disagreement or dispute with the Company or the Company’s Board of Directors on any matter relating to the operations, policies or practices of the Company.

In connection
with Prof. Wong’s resignation, the Nominating Committee nominated Huang Bo to serve as independent director. The Board determined
that Mr. Huang qualifies as an independent director under applicable Nasdaq rules and Rule 10A-3 of the United States Securities and
Exchange Act of 1934, as amended, and appointed Mr. Huang, as independent director, Chairman of the Compensation Committee
and member of the Audit Committee and Nomination Committee. Mr. Huang’s appointment is effective as of October 24, 2025.

Huang Bo
is the General Manager of Shenzhen Key Lock Biotechnology Co., Ltd., a company whose sole owner also owns 100% of Guangdong Key Lock
Health Management Co., Ltd., a key business partner of EUDA which is responsible for giving EUDA its current right to sell and distribute
certain third-party-developed stem cell therapies in Singapore and Malaysia, and cell immunotherapies in Malaysia. The Board has considered
Mr. Huang